Glioblastoma Multiforme Treatment Market - By Treatment Type, By Gender, By End Use - Global Forecast, 2025 - 2034

Glioblastoma Multiforme Treatment Market Size

The global glioblastoma multiforme treatment market was valued at USD 3.6 billion in 2024. The market is expected to grow from USD 3.9 billion in 2025 to USD 8.3 billion in 2034 at a CAGR of 8.9%. The market growth was significantly driven by the global increase in the prevalence of glioblastoma multiforme (GBM) disease. For example, as per the National Brain Tumor Society report, GBM accounts for 50.1 percent of all primary malignant brain tumors.
 

Additionally, it is estimated that more than 10,000 deaths are caused due to GBM annually. This global burden necessitates the need for novel drug therapies to provide effective treatment. To meet the demand, the market is further driven by core pharmaceutical companies funding research and development activities focused on expanding the studies to innovate effective treatment options. For example, Lisata Therapeutics,. announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed GBM. Thus, the increasing investigator-initiated study, leads to the development of more sophisticated treatment for GBM, fostering market growth.
 

Furthermore, the growing support from the regulatory authorities such as U.S. Food and Drug Administration (FDA) and European Medicine Agency for the approval of new drugs, growing the interest of key pharmaceutical companies to invest in GBM research. For example, in December 2021, Sapience Therapeutics, received fast track designation to its lead program investigating ST101 for the treatment of recurrent GBM from U.S. FDA. ST101 aimed to improve outcomes for patients suffering from GBM. This growing interest and accelerated research activities tends to fuel the market growth In addition, growing demand for personalized medicine raises the demand for next-generation sequencing and biomarkers based therapies further bolstering the market growth.
 

Glioblastoma (GBM) is also referred to as a grade IV astrocytoma, a fast-growing and aggressive brain tumor. It mainly occurs in the brain de novo or evolves from lower-grade astrocytoma invading the nearby brain tissue. In adults, GBM occurs most often in the cerebral hemisphere, especially in the frontal and temporal lobes of the brain.
 

Glioblastoma Multiforme Treatment Market Trends

The significant expansion in the glioblastoma multiforme treatment industry is primarily attributed to increased investments in research and development and partnership activities accelerating product development and innovations.
 

• The pharmaceutical companies are heavily investing in research to accelerate the development of innovative therapies focused on improving bioavailability and treatment effectiveness catering to the GBM burden.
   
• In addition, growing government and organization support towards research for innovative therapy further fuels the market demand. For instance, in 2022 the U.S. National Institutes of Health (NIH) funded brain cancer research at the level of USD 435 million, which contributed to the advancement in therapeutics development. In the same year, the Australian Government provided over USD 5.4 million for brain cancer research through the Medical Research Future Fund. These fundings are anticipated to accelerate the study broadening the growth of the market.
   
• Furthermore, such investments are creating new innovative therapies with effective results for treating GBM patients. For example, Gilead Sciences, working with University of Pennsylvania, developed a CAR-T cell therapy that targets EGFR and IL13Rα2, showing tumor shrinkage in 62% of patients with recurrent GBM. Similarly,, the approval of teserpaturev (Delytact), an oncolytic virus therapy in Japan, highlighted an astonishing one-year survival rate of 84.2% in patients with remaining or recurrent GBM.
   
• Thus, these advancements, supported by substantial investments in research and development and collaborative efforts, are shifting the GBM treatment paradigm towards more accessible therapies with better clinical outcomes for patients.
   

Glioblastoma Multiforme Treatment Market Analysis

In 2021, the global market was valued at USD 2.9 billion. The following year, it saw a slight increase to USD 3.3 billion in 2023, the market further climbed to USD 3.6 billion by 2024.
 

Based on treatment type, the global glioblastoma multiforme treatment market is segmented into non-pharmacological treatment and pharmacological treatment. The non-pharmacological segment dominated the market and was valued at USD 2.4 billion in 2024 and is poised to reach USD 5.4 billion by 2034 at a CAGR of 8.5%.
 

• The popularity of non-pharmacological segments was primarily driven due to its effectiveness attained from surgeries and radiation therapy.
   
• The expanding innovations and advancements of diagnostic devices and techniques has urged preference for these treatments. For example, Tumor Treating Fields (TTFields) therapy has emerged as a promising therapy for the treatment of GBM. It disrupts the cell division in cancerous cells through application of electric fields making it one of the effective therapies.
   
• Furthermore, the inclination of patients towards alternatives due to the limitations of conventional pharmacological treatment such as resistance to the treatment and adverse side effects including nausea, immunosuppression, and fatigue have propelled the demand for non-pharmacological treatment demand.
   
• Thus, increased awareness towards non-invasive low-side-effect treatments due to the aggressive nature of GBM and the high toxicity of standard therapies continue to fuel market growth.
   

Based on gender, the global glioblastoma multiforme treatment market is categorized into male and female. The male segment accounted for the highest market share of 61.2% in 2024 and is poised to grow at a substantial rate during the analysis period.
 

• The high occurrence of GBM in males is expected to enhance the treatment demand thereby fostering the growth of the market.
   
• For instance, as per an article published in Springer Journal, it has been reported that GBM is more common in men, with the incidence rate of 1.57%, higher in males than in females. However, the biological differences in immune response as well as tumor biology explaining this gap in disparity further propelling the treatment demand.
   
• Furthermore, the growing focus of the pharmaceutical companies catering to developed aimed therapies for the demographic further fuels the market growth.
   
• Moreover, rising awareness along with efforts towards early diagnosis are enabling timely intervention, reinforcing the segments position in the market.
   

Based on the end use, the global glioblastoma multiforme treatment market is categorized by hospitals, cancer treatment centers, ambulatory surgical centers, and other end users. In 2024, the hospitals segment accounted for the largest share of 44.3% in the market and is anticipated to reach USD 3.7 billion by 2034 at a CAGR of 9.1%.
 

• The hospitals are at the forefront of advanced technology with tailored radiation and neurosurgical therapy devices.
   
• These facilities are highly equipped with advanced diagnostics tools dedicated to the oncology and neurology units and departments ensuring efficient treatment outcome.
   
• Furthermore, the growing rate of GBM diagnoses, remarkably in emerging and low-income countries, is augmenting the need for hospital-based GBM treatment. This trend is fueled by the increased spending on healthcare from the private and public sectors.
   
• In addition, hospitals are the primary centers for clinical studies and the implementation of advanced techniques. Thus, these setting actively collaborate with the leading pharmaceutical companies to innovate and develop advanced treatment therapy that expects to enhance the treatment outcome. For example, in November 2023, the Global Coalition for Adaptive Research collaborated with the Cure Brain Cancer Foundation introducing a GBM AGILE in Australia. It is the first patient-adaptive platform trial designed to simultaneously assess multiple potential therapies for adults newly diagnosed with and those who have recurrent GBM. The trial is termed patient-centered, as its development was completely stemmed from patients' needs.
   
• Furthermore, favorable reimbursement policies schemes supporting it provide comprehensive cancer care including major surgeries, chemotherapy, and other advanced therapies enabling them to attract a wider population base for GBM which in turn, propels the growth of the market.
   
• Thus, the aforementioned factors solidified the position of hospitals contributing to the segmental growth.
   

In 2024, North America accounted for the largest revenue of USD 1.5 billion and is projected to generate revenue of USD 3.4 billion by 2034 at a CAGR of 8.6% during the analysis period.
 

• The presence of key pharmaceutical players and academic institutes in the region that majorly focus on cancer research and invest in biological and immunotherapy treatment boosts market growth.
   
• Additionally, government programs and financing for cancer research, such as the National Institutes of Health's (NIH) programs specifically targeted at brain cancer, offer a strong basis for market expansion. For instance, in May 2025, Diakonos Oncology, a U.S-based company secured a USD 20 million private placement of Simple Agreements for Future Equity (SAFE) to accelerate the Phase II trial of dubodencel glioblastoma. The company intends to use the funds to diversify its clinical portfolio into new areas like refractory melanoma. The funding was intended to aid the research initiatives which in turn advance the efforts toward treatment development.
   
• Moreover, the increasing awareness of disease among healthcare professionals and patients, owing to rising public awareness campaigns by major organizations with effective patient support programs and patient advocacy groups in North America, raises the demand for better treatment options, thereby contributing to market growth.
   

In 2024, U.S. glioblastoma multiforme treatment market accounted for USD 1.4 billion revenue from USD 1.3 billion in 2023 and is anticipated to grow at a CAGR of 8.5% between the 2025 to 2034 period.
 

• The U.S. leadership was asserted due to the increasing GBM cases, robust research fundings, and the strong healthcare infrastructure.
   
• For instance, according to the GBM Foundation estimates, the cases of GBM are expected to surpass 14,490 new cases in 2023, indicating ineffective treatments and a much greater need for effective therapies in the U.S. These growing cases would likely spur the need for effectively novel drug therapies and treatment approaches in the country.
   
• Additionally, the increasing investment from the venture capital and biotech firms for the companies working on GBM treatment drives the market growth. For instance, the NIH invested over USD 1.3 billion in glioblastoma research with the focus of developing novel GBM therapies.
   
• Therefore, the aforementioned factors collectively strengthen the country’s prominence in the North American market.
   

Germany is poised to attain significant growth in the Europe glioblastoma multiforme treatment market.
 

• Germany’s well-developed healthcare system offers advanced diagnostic technology for the detection and treatment of GBM.
   
• In addition, the German governments and private sector institutions' ongoing work involving GBM and other cancers is also receiving funding. For example, Germany's Federal Ministry of Education and Research (BMBF) actively supports research in neurology and oncology, which includes treatment of GBM.
   
• Furthermore, the growth of the country is attributed to the increased collaboration of pharmaceutical companies with academic and research centers. Industry leaders Boehringer Ingelheim and Bayer, are currently advancing research on brain tumors and cancer which is assisting the expansion of the market.
   
• Also, raising preference for targeted therapy is further set to enhance treatment efficacy bolstering overall market growth.
   

The Asia Pacific is poised to grow at a significant growth rate in the global glioblastoma multiforme treatment market over the next few years.
 

• The region exhibits substantial growth driven by the growing aging population, sedentary lifestyles, and improved diagnostic capabilities.
   
• Regional market growth is further stimulated by the introduction of a generic version of the chemotherapy drug, for example, temozolomide. This generic, low-cost form is expected to make GBM treatment more accessible, thus further promoting the growth of the market.
   
• Additionally, the growing government initiatives in brain tumor research and expansion of healthcare infrastructure across Asia countries, further propel the market growth. For instance, the Australian Brain Tumor Mission allocated over USD 136.66 million in December 2022 to fund brain tumor research with the goal of doubling survival rates and enhancing patient health.
   
• Furthermore, the region is undergoing several collaborative initiatives from Asian countries and global pharmaceutical companies to provide sophisticated GBM therapies.
   
• Such partnerships are frequently associated with clinical trial execution, transfer of technology, and local production of treatments, which improves the regional access to advanced therapeutics.
   

India is anticipated to grow significantly within the Asia Pacific glioblastoma multiforme treatment market.
 

• The increasing adoption of targeted therapies and immunotherapy such as Nivolumab and Pembrolizumab due to their efficacy in treating GBM, drives the growth of the market.
   
• The need for new therapies to treat GBM is high in the country due to the reported brain tumors occurring at a prevalence of 5-10 per 100,000 people, constituting 2% of all malignant tumors, found to be growing in frequency.
   
• Furthermore, the rising investment by pharmaceutical companies and increasing funding for cancer research by Indian government has driven the market growth. For instance, the Government of India allocated over USD 300 million for oncology research and development, promoting clinical trials and access to global standard treatment
   
• For instance, the growth of the Indian economy is aided by the fact that the country's pharmaceuticals sector is valued for approximately USD 50 billion in FY 2023-24 and is expected to reach USD 130 billion by year 2030. With strides as the biggest manufacturer of generic drugs in the world, it is largely bound to enhance the access and affordability of the GBM treatment therapeutics.
   

Brazil is projected to witness significant growth in Latin America glioblastoma multiforme treatment market in coming years.
 

• The Brazilian market has a considerable opportunity for treatment of glioblastoma multiforme owing to their strong clinical research infrastructure, supportive government policies, and diverse population.
   
• The country’s Unified Health System (SUS) provides broad access to various cancer therapies including emerging treatments such as immunotherapy and precision medicine.
   
• In addition, the expanding production of generics and biosimilars are making GBM treatment more economically accessible and positively impacting the country's pharmaceutical industry.
   
• Further, the conducting of clinical trials within the country alongside international collaboration with pharmaceutical industries is contributing positively toward innovation of therapies for GBM.
   

Saudi Arabia is anticipated to grow in the Middle East and African glioblastoma multiforme treatment market.
 

• Saudi Arabia is set to show prominent growth owing to the substantial investment in healthcare infrastructure and advanced oncology services.
   
• The country’s spearheading neuro-oncology institutions such as the King Fahad Medical City, King Faisal Specialist Hospital and Research Centre (KFSHRC) and the National Neuroscience Institute provides advanced treatments in neurology and oncology department such as CAR T cell therapy and genomic medicine aiding advanced treatment options, thereby contributing to market growth.
   
• In addition, the deployment of artificial intelligence (AI) diagnostic clinics to further augment early detection and tailored treatment approaches showcases the country’s efforts towards adopting AI to medicine.
   
• Thus, the aforementioned factors collectively reinforced the country’s adoption of oncology and precision medicines, positioning Saudi Arabia to lead the region's glioblastoma multiforme treatment in the Middle East and Africa.
   

Glioblastoma Multiforme Treatment Market Share

The top 5 players in the global glioblastoma multiforme treatment industry accounted for ~55% of the share. The market is highly competitive driven by the matrix of innovative biotechnology and pharmaceutical companies. Key companies include Amgen, Merck, F. Hoffmann La Roche, Teva Pharmaceuticals and Pfizer offering distinct therapeutic approaches such as targeted therapies, immunotherapies, and TTFields, respectively. Moreover, the emerging companies such as Lantern Pharma, Curtana Pharmaceuticals, and Denovo Biopharma are developing next-generation therapies including targeted small molecules and personalized vaccines development. Meanwhile, Amneal, Pfizer, and Teva are expanding the market with their generic and supportive care products.
 

Competitive space is further enriched by strategic partnerships, and the FDA designations such as fast track approvals for, along with the ongoing advancements in research pertaining to immuno-oncology and precision medicine. Further, with high unmet clinical needs, the market continues to attract investments focused on improving treatment delivery systems, gene therapies and combinational regimens aimed at enhancing the clinical outcomes.
 

Glioblastoma Multiforme Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are into clinical phase development. Prominent players operating in the market are as mentioned below:

• Amgen
• Amneal Pharmaceuticals
• Azurity Pharmaceuticals
• Curtana Pharmaceuticals
• Denovo Biopharma
• F. Hoffmann La Roche (Genentech)
• Karyopharm Therapeutics
• Merck
• NextSource Pharma
• Novocure
• Pfizer
• Sumitomo Dainippon Pharma
• Sun Pharmaceutical Industries
• Teva Pharmaceuticals

• Genentech, a subsidiary of Roche offers Avastin with strong clinical support for recurrent GBM management. Its sustained company growth and innovations in neuro oncology are supported by expanding oncology pipelines and therapeutic marker studies.
   
• Merck is evaluating its immunotherapy drugs such as Keytruda in GBM trials showcasing its efforts to expanding applications of immune oncology. The company’s robust research and development investment and global presence enable strategic collaborations aimed at targeting cancers such as GBM.
   
• Novocure has revolutionized the treatment of GBM with the FDA’s approval of the TTFields device, Optune. As a non-invasive therapy, it improves survival outcomes with minimal systemic effects, solidifying Novocure’s status as a leader in cancer treatment technology utilizing electrical fields.
   

Glioblastoma Multiforme Treatment Industry News

• In November 2024, Novocure’s received U.S. FDA approval for its application for new Head Flexible Electrode (HFE) transducer arrays intended for the Optune Gio system to treat GBM in adult patients. This is considered a significant development in non-invasive therapy for the treatment of GBM.
   
• In October 2024, Lantern Pharma's LP-184 has been granted fast track designation by the FDA for GBM and is anticipated to initiate a Phase 1b/2a trial in patients with recurrent GBM later this year or early next year. This designation highlighted the need for new treatment options in: LP-184's ability to target critical central nervous system cancer treatment gaps, enabling more effective and prolonged treatment options.
   
• In October 2023, Cellipont Bioservices entered into a collaborative agreement for the process development and cGMP manufacturing of DOC1021, an autologous dendritic cell vaccine designed for growing GBM as well as other cancers. This collaboration enables the further development of tailored immunotherapies for use in cancer treatment.
   

The glioblastoma multiforme treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Non-pharmacological treatment
  • Surgery
  • Radiation therapy
  • Tumor treating field therapy 
• Pharmacological treatment
  • By type
    • Chemotherapy
    • Targeted therapy
  • By durg class
    • Temozolomide
    • Bevacizumab
    • Lomustine
    • Carmustine wafers
  • By dosage form
    • Oral
    • Parenteral

Market, By Gender

• Male
• Female

Market, By End Use

• Hospitals
• Cancer treatment centers
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE